Clinical trials in Innsbruck – page 6

362 clinical trials in Innsbruck, Austria across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Innsbruck at a glance

362

clinical trials

Research sites2

Quick filters

362 trials in Innsbruck

Open in trial search

Chronic lymphocytic leukaemia+1

Recruiting

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:BGB-16673
Sponsor:BeOne Medicines AG

Contact Research Centre

Allogenic stem cell transplantation

Recruiting

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Ospedale Pediatrico Bambino Gesu

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:AZD8205
Sponsor:AstraZeneca AB

Contact Research Centre

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Congenital cystic kidney disease

Recruiting

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug

Austria

Participants:18–64 years
Substances:Dapagliflozin
Sponsor:University Of Cologne

Contact Research Centre

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Amgen Inc.

Contact Research Centre

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Vorasidenib
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:DB-1303
Sponsor:BioNTech SE

Contact Research Centre

Ischaemic stroke

Recruiting

Study of cangrelor and acetylsalicylic acid in patients with ischemic stroke requiring emergency carotid artery stenting and mechanical thrombectomy

Registered drugNo placebo

Study of cangrelor and acetylsalicylic acid in patients with ischemic stroke requiring emergency carotid artery stenting and mechanical thrombectomy

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid
Sponsor:Medical University Of Graz

Contact Research Centre

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Glioblastoma

Recruiting

Study of iodofalan (131I) and lomustine combination therapy compared to lomustine alone in patients with first recurrent glioblastoma

Registered drugNo placebo

Study of iodofalan (131I) and lomustine combination therapy compared to lomustine alone in patients with first recurrent glioblastoma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Lomustine
Sponsor:Telix Pharmaceuticals (Innovations) Pty Limited

Contact Research Centre

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Innsbruck

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on innovative treatments for various cancers, including bladder cancer, breast cancer, and gastric cancer. Studies evaluate novel combination therapies and targeted treatments to improve patient outcomes.

Non-muscle invasive bladder cancer treatment
HER2-positive cancer therapies
Glioblastoma management

Research emphasizes personalized medicine approaches and innovative drug combinations.

02 Neurological Disorders

Groundbreaking studies examining treatments for multiple sclerosis and other neurological conditions. Research focuses on testing new therapeutic agents and evaluating their effectiveness in managing disease progression.

Multiple sclerosis treatment innovations
Brain structure and function studies
Neurological response assessment

Trials aim to advance understanding of disease mechanisms and improve treatment outcomes.

03 Inflammatory Conditions

Clinical investigations into chronic inflammatory diseases, including Crohn's Disease and ulcerative colitis. Studies evaluate novel therapeutic approaches and combination treatments.

Gastrointestinal inflammation management
Chronic rhinosinusitis treatment
Inflammatory response modulation

Research focuses on improving quality of life for patients with chronic inflammatory conditions.

Back to Austria All countries